Bioskryb
2 known investors
BioSkryb Genomics develops single-cell multiomics technology, including its patented primary template-directed amplification (PTA) method and ResolveDNA, ResolveOME kits and BaseJumper bioinformatics platform, to analyze the genome, transcriptome, and surface proteins of individual cells. Its products serve research, biopharma, diagnostics, and AI-driven precision medicine partners working in oncology, neurology, and clinical development.
Investors Β· 2
In the news
Frequently asked questions
- What does Bioskryb do?
- BioSkryb Genomics develops single-cell multiomics technology, including its patented primary template-directed amplification (PTA) method and ResolveDNA, ResolveOME kits and BaseJumper bioinformatics platform, to analyze the genome, transcriptome, and surface proteins of individual cells. Its products serve research, biopharma, diagnostics, and AI-driven precision medicine partners working in oncology, neurology, and clinical development.
- Who are Bioskryb's investors?
- Bioskryb's investors include Anzu Partners, Seed Healthcare.